Cingulate Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cingulate Therapeutics, Inc. - overview
Established
2012
Location
-, KS, US
Primary Industry
Biotechnology
About
Founded in 2012 and based in Kansas, US, Cingulate Therapeutics, Inc. operates as a biopharmaceutical company that develops medications for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). The firm trades under the NASDAQ stock exchange under the ticker symbol CING. In February 2024, Cingulate Therapeutics, Inc.
raised USD 7. 5 million in a private placement by selling 3. 75 million shares at USD 2 per share on the NASDAQ. The firm as of July 2024, is led by its co-founders, Shane J.
Schaffer (Chairman and CEO) and Raul R. Silva (CSO). The clinical-stage biopharmaceutical company specializes in developing treatments for central nervous system disorders. With a focus on addressing the substantial market for ADHD and anxiety medications in the United States, Cingulate leverages its proprietary Precision Timed Release™ (PTR™) platform technology.
This platform allows for the development of next-generation pharmaceuticals designed to enhance treatment outcomes by delivering precise doses over extended periods, minimizing side effects associated with traditional dosing regimens. Cingulate's pipeline includes CTX-1301 and CTX-1302 for ADHD, and CTX-2103 for anxiety.
Current Investors
Werth Family Investment Associates
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.cingulatetherapeutics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.